Skip to main content
MNKD
NASDAQ Life Sciences

CEO Michael Castagna Purchases $259,000 in Company Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.725
Mkt Cap
$839.574M
52W Low
$2.522
52W High
$6.51
52W Position info
8.1% above low
Off High info
58% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

MNKD is trading near its 52-week low of $2.522 (8.1% above the low).

Summary

MannKind's CEO, Michael Castagna, purchased $259,000 worth of common stock in an open-market transaction, demonstrating executive confidence following recent financial reports.


Key Events · Ownership and Investor Activity · MNKD

  • CEO Stock Purchase

    Michael Castagna, CEO and Director, acquired 100,000 shares of common stock for a total of $259,000 at an average price of $2.59 per share on March 10, 2026.

  • Executive Confidence Signal

    This open-market purchase by the top executive indicates strong belief in the company's value and future performance, especially following the recent Q4 and full-year 2025 earnings report on February 26, 2026.


Analysis · MNKD · Life Sciences

Michael Castagna, CEO and Director of MannKind Corporation, made a significant open-market purchase of company stock, investing $259,000. This transaction, occurring shortly after the company reported its Q4 and full-year 2025 financial results on February 26, 2026, signals strong confidence from the top executive in the company's future prospects and valuation, despite a reported decline in net income.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 30.5% of the 1996 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MNKD was trading at $2.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $839.6M. The 52-week trading range was $2.52 to $6.51. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MNKD - Latest Insights

MNKD
Sep 09, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.28
Real-time Price: $3.86 info
Change: -$0.4218 (-10%) info
Market Cap: $1.219B info
MNKD
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.12
Real-time Price: $3.86 info
Change: -$0.2618 (-6%) info
Market Cap: $1.219B info
MNKD
Jul 29, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.03
Real-time Price: $3.86 info
Change: -$0.1718 (-4%) info
Market Cap: $1.219B info
MNKD
Jul 24, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.11
Real-time Price: $3.86 info
Change: -$0.2518 (-6%) info
Market Cap: $1.219B info
MNKD
Jul 24, 2026, 6:35 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.10
Real-time Price: $3.86 info
Change: -$0.2418 (-6%) info
Market Cap: $1.219B info